Veracyte, INC Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have reported a 10.1% beneficial ownership stake in Veracyte Inc as of May 29, 2026.

Artisan Partners, through its various entities, has reported beneficial ownership of 6.9% of Veracyte, Inc.'s common stock as of March 31, 2026.

State Street Corporation has reported beneficial ownership of 6.3% of Veracyte Inc.'s common stock as of March 31, 2026.

FMR LLC, along with Abigail P. Johnson, has reported a beneficial ownership of 9.7% in Veracyte Inc. as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.2% of Veracyte Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.67% in Veracyte Inc. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Veracyte Inc. due to an internal organizational realignment.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 7.2% of Veracyte Inc.'s common stock as of December 31, 2025.

Artisan Partners Asset Management Inc. and its affiliates disclosed a 7.9% beneficial ownership stake in Veracyte, Inc. common stock as of December 31, 2025.

ARK Investment Management LLC and Catherine D. Wood have jointly disclosed a beneficial ownership of 4.92% in Veracyte, Inc.'s common stock.

Artisan Partners Asset Management Inc. and its affiliates have reported a 9.4% beneficial ownership stake in Veracyte, Inc. common stock.

State Street Corporation has reported a 5.3% beneficial ownership stake in Veracyte Inc., holding 4,199,674 shares of common stock as of September 30, 2025.

FMR LLC and its affiliates, along with Abigail P. Johnson, have filed an amended Schedule 13G disclosing a beneficial ownership of 8.6% in Veracyte Inc.'s common stock.

ARK Investment Management LLC and Catherine D. Wood have disclosed a combined beneficial ownership of 5.68% in Veracyte, Inc. common stock.

Wellington Management Group and its affiliates have reduced their beneficial ownership in Veracyte, Inc. to 4.4% of common stock as of June 30, 2025.

Artisan Partners reports beneficial ownership of 8.1% of Veracyte's common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 15.2% beneficial ownership stake in Veracyte, Inc.'s common stock as of July 31, 2025.

ARK Investment Management LLC and Catherine D. Wood have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.09% in Veracyte, Inc.'s Common Stock as of May 31, 2025.

Artisan Partners Asset Management Inc. and its affiliated entities have disclosed a 6.7% beneficial ownership stake in Veracyte, Inc., holding 5,239,711 shares as of March 31, 2025.

ARK Investment Management LLC and Catherine D. Wood have jointly disclosed a beneficial ownership of 5.05% in Veracyte, Inc.'s common stock as of March 31, 2025.

ARK Investment Management LLC has filed an Amendment No. 10 to its Schedule 13G, disclosing a reduction in its beneficial ownership of Veracyte, Inc. common stock to 4.48%.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 10.2% of Veracyte Inc.'s common stock as of April 30, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly disclosed a beneficial ownership of 9.0% of Veracyte Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its beneficial ownership of 8.4% of Veracyte, Inc.'s common stock as of March 31, 2025.

Artisan Partners, through its various entities, has filed an amended Schedule 13G disclosing a beneficial ownership of 8.5% in Veracyte, Inc.'s common stock as of December 31, 2024.

ARK Investment Management LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 6.41% in Veracyte, Inc. as of September 30, 2024.